Choose Life Biotech SA

Choose Life Biotech (CLB) is a Swiss biotechnology company specializing in the preclinical development of innovative drugs through the molecular engineering of nano-antibodies (nanobodies). Founded in 2022, the company focuses on creating a proprietary library of antibodies targeting a wide range of therapeutic areas, including immunotherapy, infectious diseases, and inflammatory conditions. Headquartered in Bellinzona, the company operates within the BIOS+ (Bellinzona Institutes of Science) ecosystem and maintains close strategic ties with the Institute for Research in Biomedicine (IRB) and the Institute of Oncology Research (IOR). CLB is positioned as a high-growth startup in the rapidly expanding nanobody market, which offers significant advantages over traditional antibodies due to their smaller size and enhanced stability.